Palisade bio announces formation of clinical advisory board with appointments of preeminent key opinion leaders

Carlsbad, ca, feb. 08, 2024 (globe newswire) -- palisade bio, inc.  (nasdaq: pali) (“palisade” or the “company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (gi) diseases, today announced the appointments of bruce sands, md, ms and florian rieder, md to its clinical advisory board (cab). drs. sands and rieder will be advising palisade on the advancement of its product candidates from preclinical studies to clinical trials.
PALI Ratings Summary
PALI Quant Ranking